Ceptaris Therapeutics Raises $10M in Series D-1 Funding

Ceptaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company, has raised $10m in Series D-1 funding.

Backers include existing investors Vivo Ventures, Palo Alto Investors, Burrill & Company, Aperture Venture Partners, Osage and BioAdvance, and new investor, Third Point, LLC.

The funding will be used for operational expenses, including activities related to addressing the FDA’s requests.

Led by Stephen Tullman, President and CEO, Ceptaris recently received a Complete Response Letter from the Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).



Join the discussion